Oxford BioMedica plc (OXB) Insider Martin Diggle Acquires 100,000 Shares
Oxford BioMedica plc (LON:OXB) insider Martin Diggle acquired 100,000 shares of Oxford BioMedica plc stock in a transaction dated Friday, September 15th. The stock was purchased at an average cost of GBX 8 ($0.10) per share, for a total transaction of £8,000 ($10,331.91).
Martin Diggle also recently made the following trade(s):
- On Thursday, August 31st, Martin Diggle sold 2,377,600 shares of Oxford BioMedica plc stock. The shares were sold at an average price of GBX 10 ($0.13), for a total value of £237,760 ($307,064.45).
- On Friday, September 1st, Martin Diggle acquired 320,000 shares of Oxford BioMedica plc stock. The stock was purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £28,800 ($37,194.89).
- On Thursday, July 13th, Martin Diggle acquired 660,000 shares of Oxford BioMedica plc stock. The stock was purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £59,400 ($76,714.45).
Oxford BioMedica plc (LON:OXB) traded down 2.74% on Friday, reaching GBX 7.81. The company had a trading volume of 2,638,720 shares. The stock’s market cap is GBX 241.19 million. Oxford BioMedica plc has a one year low of GBX 2.98 and a one year high of GBX 11.25. The company has a 50-day moving average of GBX 8.90 and a 200 day moving average of GBX 6.56.
Several equities analysts have recently weighed in on the company. N+1 Singer lifted their price objective on Oxford BioMedica plc from GBX 8.70 ($0.11) to GBX 10.20 ($0.13) and gave the company a “hold” rating in a research note on Thursday, August 31st. Jefferies Group LLC restated a “buy” rating and set a GBX 13 ($0.17) price objective on shares of Oxford BioMedica plc in a report on Thursday, August 31st. Finally, Shore Capital restated a “not rated” rating on shares of Oxford BioMedica plc in a report on Thursday, July 13th.
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.